Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.

Inclusion Criteria: 2 months old infants on the day of inclusion Born at full term of pregnancy (≥ 37 weeks) with a birth weight ≥ 2.5 kg Informed consent form signed by one or both parents or by the legally acceptable representative and 1 or 2 independent witnesses Able to attend all scheduled visits and to comply with all trial procedures Has complied with the national immunization calendar (BCG for both countries) for the first 2 months of life. Exclusion Criteria: Participation in another clinical trial in the 4 weeks preceding the first trial vaccination Planned participation in another clinical trial during the present trial period Congenital or acquired immunodeficiency, immunosuppressive therapy such as long-term systemic corticosteroids therapy Subjects with congenital or acquired immunodeficiency in the child's surrounding Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances Chronic illness at a stage that could interfere with trial conduct or completion Blood or blood-derived products received since birth Any vaccination in the 4 weeks preceding the first trial vaccination Vaccination planned in the 4 weeks following the trial vaccination Documented history of pertussis, tetanus, diphtheria, poliomyelitis, Haemophilus influenzae type b or hepatitis B infection(s) (confirmed either clinically, serologically or microbiologically) Mother known as seropositive for HIV or Hepatitis C, or known carrier of Hepatitis B surface antigen Previous vaccination against pertussis, tetanus, diphtheria, poliomyelitis, or Haemophilus influenzae type b infection(s) Coagulopathy, thrombocytopenia or a bleeding disorder contraindicating IM vaccination History of seizures Febrile or acute illness on the day of inclusion.